Abstract:Linear ethers such as polyethylene glycol have extensive industrial and medical applications. Additionally, phospholipids containing an ether linkage between the glycerol backbone and hydrophobic tails are prevalent in human red blood cells and nerve tissue. This study uses ab initio results to revise the CHARMM additive (C36) partial-charge and dihedral parameters for linear ethers and develop parameters for the ether-linked phospholipid 1,2-di- O-hexadecyl- sn-glycero-3-phosphocholine (DHPC). The new force f… Show more
“…77 The ether oxygen and bonded carbon of the tail received charges consistent with the recently published linear ether FF, C36e. 78 In this study, it was found that reducing the C3 glycerol charge relative to QM results for linear ethers allows more water to penetrate the bilayer, improving agreement with the overall experimental surface area per lipid (based on F(q) crossing points). Because the glycerol linkage is branched rather than linear, borrowing partial charge from C36 results tuned specifically to the glycerol region of lipids is chemically consistent.…”
Section: Force Field Development and Validationsupporting
Ethanolamine plasmalogen (EtnPLA) is a conicalshaped ether lipid and an essential component of neurological membranes. Low stability against oxidation limits its study in experiments. The concentration of EtnPLA in the bilayer varies depending on cell type and disease progression. Here we report on mixed bilayers of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and 1-(1Z-octadecenyl)-2-oleoyl-sn-glycero-3-phosphoethanolamine (C18(Plasm)-18:1PE, PLAPE), an EtnPLA lipid subtype, at mole ratios of 2:1, 1:1, and 1:2. We present X-ray diffuse scattering (XDS) form factors F(q z) from oriented stacks of bilayers, related electron-density profiles, and hydrocarbon chain NMR order parameters. To aid future research on EtnPLA lipids and associated proteins, we have also extended the CHARMM36 all-atom force field to include the PLAPE lipid. The ability of the new force-field parameters to reproduce both X-ray and NMR structural properties of the mixed bilayer is remarkable. Our results indicate a thickening of the bilayer upon incorporation of increasing amounts of PLAPE into mixed bilayers, a reduction of lateral area per molecule, and an increase in lipid tail-ordering. The lateral compressibility modulus (K A) calculated from simulations yielded values for PLAPE similar to POPC.
“…77 The ether oxygen and bonded carbon of the tail received charges consistent with the recently published linear ether FF, C36e. 78 In this study, it was found that reducing the C3 glycerol charge relative to QM results for linear ethers allows more water to penetrate the bilayer, improving agreement with the overall experimental surface area per lipid (based on F(q) crossing points). Because the glycerol linkage is branched rather than linear, borrowing partial charge from C36 results tuned specifically to the glycerol region of lipids is chemically consistent.…”
Section: Force Field Development and Validationsupporting
Ethanolamine plasmalogen (EtnPLA) is a conicalshaped ether lipid and an essential component of neurological membranes. Low stability against oxidation limits its study in experiments. The concentration of EtnPLA in the bilayer varies depending on cell type and disease progression. Here we report on mixed bilayers of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and 1-(1Z-octadecenyl)-2-oleoyl-sn-glycero-3-phosphoethanolamine (C18(Plasm)-18:1PE, PLAPE), an EtnPLA lipid subtype, at mole ratios of 2:1, 1:1, and 1:2. We present X-ray diffuse scattering (XDS) form factors F(q z) from oriented stacks of bilayers, related electron-density profiles, and hydrocarbon chain NMR order parameters. To aid future research on EtnPLA lipids and associated proteins, we have also extended the CHARMM36 all-atom force field to include the PLAPE lipid. The ability of the new force-field parameters to reproduce both X-ray and NMR structural properties of the mixed bilayer is remarkable. Our results indicate a thickening of the bilayer upon incorporation of increasing amounts of PLAPE into mixed bilayers, a reduction of lateral area per molecule, and an increase in lipid tail-ordering. The lateral compressibility modulus (K A) calculated from simulations yielded values for PLAPE similar to POPC.
“…1). 3,10,11 However, as also shown in Figure 1, any deviation from the 12 Å cutoff in LJ leads to dramatic change in bilayer surface areas, and, as follows from the hexadecane results, surface tensions of alkane/air interfaces. This inconsistency was recognized in the original publication of C36, 1 but it was not possible to rectify the problem at that time because an efficient method for calculating long-range LJ interactions was not supported in CHARMM 12 and other major simulation programs.…”
Section: Introductionmentioning
confidence: 54%
“…1,2-dipropionyl-sn-glycero-3-phosphocholine C3-PC 3:0 3:0 1,2-dilauroyl-sn-glycero-3-phosphorylcholine DLPC 12:0 12:0 1,2-dimyristoyl-sn-glycero-3-phosphorylcholine DMPC 14:0 14:0 1,2-dipalmitoyl-sn-glycero-3-phosphocholine DPPC 16:0 16:0 1,2-dimyristoyl-sn-glycero-3-phospho-(1'-rac-glycerol) DMPG 14:0 14:0 DPPC is the linkage between the head group and tails, which can be parametrized separately as indicated by the parametrization of C36 lipid FF for ether lipids. 3 The second consideration is what properties should be covered in the training set. As commonly used benchmarks for lipid FF development, surface areas and membrane thicknesses were included.…”
Section: Lipids Covered and Nomenclaturesmentioning
confidence: 99%
“…Since its release in 2010, the CHARMM36 (C36) lipid force field (FF) 1 has been extended to include anionic lipids, 2 ether lipids, 3 ceramides, 4,5 glycolipids, 6 plasmalogens, 7 and polyunsaturated tails. 8 The C36 lipid FF is heavily utilized due to the diversity of lipids it covers and the well-parametrized potential parameters.…”
Long-range Lennard-Jones (LJ) interactions have been incorporated into the CHARMM36 (C36) lipid force field
(FF) using the LJ particle-mesh Ewald (LJ-PME) method in order to remove the inconsistency of bilayer and
monolayer properties arising from the exclusion of long-range dispersion [citation to paper I]. The new FF is
denoted C36/LJ-PME. While the first optimization was based on three phosphatidylcholines (PCs), this paper
extends the validation and parametrization to more lipids including PC, phosphatidylethanolamine (PE),
phosphatidylglycerol (PG) and ether lipids. The agreement with experimental structure data is excellent for PC,
PE and ether lipids. C36/LJ-PME also compares favorably with scattering data of PG bilayers but less so with
NMR deuterium order parameters of 1,2-dimyristoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (DMPG) at 303.15
K, indicating a need for future optimization regarding PG-specific parameters. Frequency dependence of NMR
T1 spin-lattice relaxation times is well described by C36/LJ-PME and the overall agreement with experiment is
comparable to C36. Lipid diffusion is slower than C36 due to the added long-range dispersion causing a higher
viscosity, although it is still too fast compared to experiment after correction for periodic boundary conditions.
When using a 10 Å real-space cutoff, the simulation speed of C36/LJ-PME is roughly equal to C36. While more
lipids will be incorporated into the FF in the future, C36/LJ-PME can be readily used for common lipids and
extends the capability of the CHARMM FF by supporting monolayers and eliminating the cutoff dependence.<br>
“…[13][14][15][16][17] The CHARMM36 (C36) set has been especially successful. It covers many important lipid types 14,[18][19][20][21][22][23][24] and is well-validated for various properties such as bilayer areas, compressibilities, spontaneous curvature, and bending constants. 25 However, monolayer surface tensions from C36 substantially underestimate experiment, 14 as expected from the lack of long-range dispersion.…”
The development of the CHARMM lipid force field (FF) can be traced back to the early 1990s with its current
version denoted CHARMM36 (C36). The parametrization of C36 utilized high-level quantum mechanical data
and free energy calculations of model compounds before parameters were manually adjusted to yield agreement
with experimental properties of lipid bilayers. While such manual fine-tuning of FF parameters is based
on intuition and trial-and-error, automated methods can identify beneficial modifications of the parameters via
their sensitivities and thereby guide the optimization process. This paper introduces a semi-automated approach
to reparametrize the CHARMM lipid FF with consistent inclusion of long-range dispersion through the LennardJones particle-mesh Ewald (LJ-PME) approach. The optimization method is based on thermodynamic
reweighting with regularization with respect to the C36 set. Two independent optimizations with different
topology restrictions are presented. Targets of the optimizations are primarily liquid crystalline phase properties
of lipid bilayers and the compression isotherm of monolayers. Pair correlation functions between water and lipid
functional groups in aqueous solution are also included to address headgroup hydration. While the physics of the
reweighting strategy itself is well understood, applying it to heterogeneous, complex anisotropic systems poses
additional challenges. These were overcome through careful selection of target properties and reweighting
settings allowing for the successful incorporation of the explicit treatment of long-range dispersion, and we denote
the newly optimized lipid force field as C36/LJ-PME. The current implementation of the optimization protocol
will facilitate the future development of the CHARMM and related lipid force fields.<br>
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.